Valbiotis S.A.S. (ALVAL)
Market Closed
10 Aug, 15:30
XPAR 
€
0. 81
+0.01
+1.2438%
€
20.34M Market Cap
- P/E Ratio
- Div Yield
75,949 Volume
-0.84 Eps
€ 0.8
Previous Close Want to track ALVAL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALVAL closed today higher at €0.81, an increase of 1.2438% from yesterday's close, completing a monthly increase of 1.4963% or €0.01. Over the past 12 months, ALVAL stock gained 15.9544%.
ALVAL is not paying dividends to its shareholders.
The last earnings report, released on Mar 02, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Valbiotis S.A.S. has completed 2 stock splits, with the recent split occurring on Jun 10, 2025.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XDUS (EUR).
Valbiotis S.A.S. (ALVAL) FAQ
What is the stock price today?
The current price is €0.81.
On which exchange is it traded?
Valbiotis S.A.S. is listed on XPAR.
What is its stock symbol?
The ticker symbol is ALVAL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 20.34M.
Has Valbiotis S.A.S. ever had a stock split?
Valbiotis S.A.S. had 2 splits and the recent split was on Jun 10, 2025.
Valbiotis S.A.S. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Sebastien Peltier HDR, Ph.D. CEO | XPAR Exchange | FR0013254851 ISIN |
| FR Country | 52 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Valbiotis SA is a pioneering French company dedicated to the research and development of nutrition-based health solutions aimed at the prevention and control of metabolic and cardiovascular diseases. Established in 2014, with its headquarters in Périgny, France, Valbiotis represents a progressive approach in addressing some of the most prevalent health issues today through natural health products. Building on a strategic partnership with Nestlé Health Science, the company underscores its commitment to global health improvement and the development of scientifically validated preventive treatments. This collaboration highlights the alignment of Valbiotis SA’s innovative endeavors with leading expertise in the health sciences sector.
Products and Services
- TOTUM-63: Designed as a preventive solution against type 2 diabetes, TOTUM-63 is the flagship product of Valbiotis SA. This innovative formulation aims to address the ever-increasing challenge of diabetes through a natural, scientifically backed method.
- TOTUM-070: Currently in Phase II/III clinical trials, TOTUM-070 represents Valbiotis SA’s commitment to combating hypercholesterolemia, a condition characterized by high cholesterol levels that significantly increase the risk of heart disease. This product is a testament to the company’s focus on cardiovascular health.
- TOTUM-854: With a focus on arterial hypertension, TOTUM-854 is undergoing Phase II/III clinical trials. This condition, known for its role in increasing the risk of heart attacks, strokes, and other health issues, is being targeted by Valbiotis with a novel approach aiming at prevention and control through natural health products.
- TOTUM-448: Dedicated to the treatment of patients with MASLD (Metabolically Associated Steatohepatitis Liver Disease), TOTUM-448 is part of Valbiotis' broader mission to address metabolic diseases at various levels, showcasing the company's comprehensive approach to health nutrition-based disease prevention and control.
Contact Information
Address: rue Paul Vatine, Périgny, France, 17180
Phone: 33 5 46 28 62 58
Website: https://www.valbiotis.com
